Industry sponsored studies twice as likely to have positive conclusions about costs

BMJ 2003; 327 doi: 10.1136/bmj.327.7422.1006-b (Published 30 October 2003)
Cite this as: BMJ 2003;327:1006.3

Access to the full text of this article requires a subscription or payment. Please log in or subscribe below.

  1. Roger Dobson
  1. Abergavenny

    Researchers have warned of the risk of sponsorship bias in health economic studies in the field of cancer.

    Industry sponsored studies were twice as likely to be cost minimisation analyses, which compare equally effective treatments on the basis of costs. The industry studies were 2.5 times …

    Access to the full text of this article requires a subscription or payment

    Article access

    Article access for 1 day

    Purchase this article for £20 $30 €32*

    The PDF version can be downloaded as your personal record

    * Prices do not include VAT

    THIS WEEK'S POLL